Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation.
Liver transplantation (LT) is the standard therapeutic approach for the treatment of end-stage acute and chronic autoimmune liver disease as autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Results of liver transplantation in these indications are good with a patient survival after LT at 5 years of 85%. However several series have reported a possible recurrence of primary autoimmune liver disease after liver transplantation. Concerning all these three autoimmune liver diseases, recurrence of the disease on the graft may have multiple clinical, biochemical, histological and radiological expression influenced by different factors as the diagnostic methods used, the degree of immunosuppression and the genetic background of the recipient. We would like with this overview to describe the different pattern of recurrence of these autoimmune liver disease, their potential influence on the liver graft and their therapeutic management.
Duclos-Vallée
Jean-Charles
JC
Centre Hépato-Biliaire, UPRES EA 3541, Hôpital Paul-Brousse, Assistance Publique-Hôpitaux de Paris, Villejuif, France. jean-charles.duclos-vallee@pbr.ap-hop-paris.fr
D015209:Cholangitis, Sclerosing / Q000209:etiology* / Q000601:surgery; D019693:Hepatitis, Autoimmune / Q000209:etiology* / Q000601:surgery; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000209:etiology* / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence